1. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection 
Steven Flamm, K. Rajender Reddy, Neddie Zadeikis, Tarek Hassanein, Bruce R. Bacon, Andreas Maieron, Stefan Zeuzem, Marc Bourliere, Jose L. Calleja, Matthew P. Kosloski, Rajneet K. Oberoi, Chih-Wei Lin, Yao Yu, Sandra Lovell, Dimitri Semizarov, Federico J. Mensa 
Clinical Gastroenterology and Hepatology 
Volume 17, Issue 3, Pages e6 (February 2019)
DOI: /j.cgh
Copyright © 2019 AGA Institute Terms and Conditions

2. Figure 1
SVR12 for each ARA by ITT and mITT analyses. G/P efficacy defined as SVR12 reported for each ARA overall (A) by ITT and mITT analyses. SVR12 data further stratified by HCV genotype for each ARA using ITT (B) and mITT (C) analyses.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

3. Figure 2
SVR12 for high- and low-dose PPI users by ITT and mITT analyses. G/P efficacy defined as SVR12 reported overall and stratified by HCV genotype for each ARA using ITT (A) and mITT (B) analyses.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

4. Supplementary Figure 1 Patient disposition.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions